Clinical trial

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Pardoprunox Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-02-01

PhasePHASE3

Conditions

Early Stage Parkinson's Diseaseunresolved

Interventions

PardoprunoxDRUG

Sponsors & collaborators

Solvay Pharmaceuticalslead sponsor

Mapped research locations

Buenos AiresArgentina6 MoscowRussia4 SofiaBulgaria4 Saint PetersburgRussia3 BelgradeSerbia3 ZagrebCroatia3 BogotáColombia3 St LouisMissouri, United States2 KyivUkraine2 KharkivUkraine2 BratislavaSlovakia2 Cape TownSouth Africa2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00332917 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.